Neutral nanotransporters

1. A composition comprising:

a hydrophobic modified polynucleotide, wherein the hydrophobic modified polynucleotide is a double-stranded RNA comprising a blunt end; and

a neutral fatty mixture;

wherein the hydrophobic modified polynucleotide and the neutral fatty mixture form a micelle and wherein between 40-100% of the nucleotides of the hydrophobic modified polynucleotide are chemically modified nucleotides.

2. The composition of claim 1 , wherein the neutral fatty mixture comprises a DOPC (dioleoylphosphatidylcholine).

3. The composition of claim 1 , wherein the neutral fatty mixture comprises a DSPC (distearoylphosphatidylcholine).

4. The composition of claim 2 , wherein the neutral fatty mixture further comprises a sterol.

5. The composition of claim 1 , wherein the neutral fatty mixture comprises 20% of a fatty acid derivative of choline.

6. The composition of claim 5 , wherein the neutral fatty mixture further comprises 20% sterol.

7. The composition of claim 4 , wherein the composition includes at least 20% DOPC and at least 20% cholesterol.

8. The composition of claim 1 , wherein the hydrophobic portion of the hydrophobic modified polynucleotide is a sterol.

9. The composition of claim 1 , wherein the hydrophobic portion of the hydrophobic modified polynucleotide is selected from the group consisting of bile acids, cholic acid, taurocholic acid, deoxycholate, oleyl lithocholic acid, oleoyl cholenic acid, glycolipids, phospholipids, sphingolipids, isoprenoids, vitamins, saturated fatty acids, unsaturated fatty acids, fatty acid esters, triglycerides, pyrenes, porphyrines, Texaphyrine, adamantane, acridines, biotin, coumarin, fluorescein, rhodamine, Texas-Red, digoxygenin, dimethoxytrityl, t-butyldimethylsilyl, t-butyldiphenylsilyl, cyanine dyes, Hoechst 33258 dye, psoralen, and ibuprofen.

10. The composition of claim 1 , wherein the polynucleotide is an isolated double stranded nucleic acid molecule comprising a guide strand and a passenger strand, wherein the guide strand is from 16-29 nucleotides long and is substantially complementary to a target gene, wherein the passenger strand is from 8-14 nucleotides long and has complementarity to the guide strand, and wherein the guide stand has a single stranded 3′ region that is 5 nucleotides or longer.

11. A method of inducing RNAi in a subject comprising:

administering to a subject an effective amount for inducing RNAi of mRNA of a target gene of the composition of claim 1 , wherein the polynucleotide has at least a region of sequence correspondence to the target gene.

12. The method of claim 11 , wherein the subject is a human.

13. The method of claim 11 , wherein the target gene is PPIB, MAP4K4, or SOD1.

14. A method for delivering a polynucleotide to a target tissue of a subject, comprising

administering to a subject a composition of claim 1 , wherein the composition includes a fatty acid in the neutral fatty mixture or cargo molecule associated with targeting to the target tissue in order to deliver the polynucleotide to the target tissue.

15. The method of claim 14 , wherein the target tissue is cardiomyocytes, lung, fat, or liver.

16. The method of claim 14 , wherein the composition includes a lipid and wherein the lipid is cardiolipin or linoleic acid.

17. A method of inducing RNAi in a subject comprising:

administering to a subject an effective amount for inducing RNAi of mRNA of a target gene of the composition of claim 1 , wherein the polynucleotide has at least a region of sequence correspondence to the target gene, wherein the step of administering is systemic, intravenous, intraperitoneal, intradermal, topical, intranasal, inhalation, oral, intramucosal or intraocular.

18. The method of claim 17 , wherein the administration is systemic.

19. The composition of claim 1 , further comprising a cargo molecule.